Kenzie L. Preston, Ph.D.
Clinical Pharmacology and Therapeutics Research Branch
251 Bayview Boulevard
Baltimore, MD 21224
The goals of our research are to develop and test the efficacy and safety of new treatments for drug abuse and to understand the individual and environmental factors that affect drug taking and relapse. Our primary focus is on evaluating treatments for cocaine and opioid abuse, including both pharmacologic and non-pharmacologic (psychosocial and behavioral) treatments. Related projects are evaluating the effects of specifically targeted counseling programs for reducing high-risk HIV-transmission behaviors, developing new screening and assessment tools (questionnaires, drug-screening methods) for testing potential treatment medications, and assessing the effects of patient characteristics (e.g., co-morbidity, family history, drug metabolism) on compliance, treatment outcome, and other clinical variables. Another major focus of our research is developing field tools to measure the effect of psychosocial stress as it actually occurs in daily life. With these tools, individuals with substance use disorders provide behavioral and physiological data in real time in their usual environments. Behavioral and physiological data are linked with a geographical location that can be codified in terms of objective ratings of neighborhood disarray, enabling us to relate indices of community-level risk to intensive field measurements of individual attempts at behavior change. The field measurements are supplemented with laboratory data from the same pool of participants, enabling assessment of dysregulation of biological responses to stress and its association with time spent in particular environments. The field tools will also enable a more sophisticated, integrative approach to the study of interactions between genes and environment in determining health outcomes.
Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL. Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry. 2009;66(1):88-94.
Kennedy AP, Epstein DH, Jobes ML, Agage D, Tyburski M, Phillips KA, Ali AA, Bari R, Hossain SM, Hovsepian K, Rahman MM, Ertin E, Kumar S, Preston KL. Continuous in-the-field measurement of heart rate: Correlates of drug use, craving, stress, and mood in polydrug users. Drug Alcohol Depend. 2015;151:159-66.
Epstein DH, Marrone GF, Heishman SJ, Schmittner J, Preston KL. Tobacco, cocaine, and heroin: Craving and use during daily life. Addict Behav. 2010;35(4):318-24.
Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57(4):395-404.
Kowalczyk WJ, Phillips KA, Jobes ML, Kennedy AP, Ghitza UE, Agage DA, Schmittner JP, Epstein DH, Preston KL. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment. Am J Psychiatry. 2015;172(8):760-7.
Related Scientific Focus Areas
This page was last updated on August 10th, 2017